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Abstract
Background: Glioma is the most commonly diagnosed primary brain tumor and is characterized by invasive and infiltrative
behavior. uPAR and cathepsin B are known to be overexpressed in high-grade gliomas and are strongly correlated with
invasive cancer phenotypes.
Methodology/Principal Findings: In the present study, we observed that simultaneous downregulation of uPAR and
cathepsin B induces upregulation of some pro-apoptotic genes and suppression of anti-apoptotic genes in human glioma
cells. uPAR and cathepsin B (pCU)-downregulated cells exhibited decreases in the Bcl-2/Bax ratio and initiated the collapse
of mitochondrial membrane potential. We also observed that the broad caspase inhibitor, Z-Asp-2, 6-dichlorobenzoyl-
methylketone rescued pCU-induced apoptosis in U251 cells but not in 5310 cells. Immunoblot analysis of caspase-9
immunoprecipitates for Apaf-1 showed that uPAR and cathepsin B knockdown activated apoptosome complex formation in
U251 cells. Downregulation of uPAR and cathepsin B also retarded nuclear translocation and interfered with DNA binding
activity of CREB in both U251 and 5310 cells. Further western blotting analysis demonstrated that downregulation of uPAR
and cathepsin B significantly decreased expression of the signaling molecules p-PDGFR-b, p-PI3K and p-Akt. An increase in
the number of TUNEL-positive cells, increased Bax expression, and decreased Bcl-2 expression in nude mice brain tumor
sections and brain tissue lysates confirm our in vitro results.
Conclusions/Significance: In conclusion, RNAi-mediated downregulation of uPAR and cathepsin B initiates caspase-
dependent mitochondrial apoptosis in U251 cells and caspase-independent mitochondrial apoptosis in 5310 cells. Thus,
targeting uPAR and cathepsin B-mediated signaling using siRNA may serve as a novel therapeutic strategy for the treatment
of gliomas.
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Introduction
Apoptosis is a tightly regulated form of programmed cell death
involving a series of biochemical events that leads to a variety of
morphological changes including membrane blebbing, cell
shrinkage, nuclear fragmentation, chromatin condensation, and
chromosomal DNA fragmentation [1,2]. The components of the
apoptotic signaling network are genetically encoded in an inactive
form and are activated by various external and internal stimuli
including DNA damage, drugs, or irradiation [3,4]. Mitochondria
play a central part in cellular survival and apoptotic death [5]. The
key events of mitochondrial apoptosis include the release of
cytochrome C, loss of mitochondrial transmembrane potential,
altered cellular oxidation-reduction, and participation of pro- and
anti-apoptotic Bcl-2 family proteins [6].
The Bcl-2 family of genes is known to be involved in the regulation
of the cell death process [7,8]. Bcl-2 and Bcl-xL are anti-apoptotic
members predominantly localized in mitochondria that regulate
mitochondrial membrane integrity and cytochrome C release. Pro-
apoptotic members, such as Bax (Bcl-2–associated X protein) and
BAD (Bcl-2-associated death promoter), mainly reside in the
cytoplasm and redistribute into mitochondria in response to death
stimuli [6,9–11]. Bcl-2 family proteins are able to undergo
homodimerization and heterodimerization, and the ratio of pro- to
anti-apoptotic proteins determines the fate of cells [12,13]. The
hallmark of glioma isincreased activity of the PI3K/Akt pathway that
controls the expression of pro-survival proteins, including NF-kB
(nuclear factor-kappaB), CREB (cAMP response element binding)
(CREB) and Bcl-2 as well as pro-apoptotic molecules such as Bax and
BAD [14–18]. CREB plays a key role in regulating neuronal survival
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regulating the transcription of several pro-survival factors, including
Bcl-2 [20,21]. In addition, in some populations of neurons, the loss of
CREB imparts a Bax-dependent form of apoptosis [22].
In the present study, we demonstrate for the first time that either
individualorsimultaneousdownregulationofuPARandcathepsinB
using siRNA decreased Bcl-2 expression and increased Bax
expression in U251 glioma cells and 5310 glioma xenograft cells
(in vitro), and in brain tumor tissue sections and tissue lysates (in vivo).
We also show that the broad caspase inhibitor, Z-Asp-2, 6-
dichlorobenzoylmethylketone rescued apoptosis in pCU-treated
U251 cells, but not in 5310 cells. In addition, uPAR and cathepsin
B downregulation decreased the expression levels of PDGFR-b,
PI3K, and Akt and also affected the promoter (DNA) binding
activity of CREB. Moreover, CREB siRNA decreased the
expression of Bcl-2, but it did not affect the expression of Bax. In
the present study, we also observed that PDGFR tyrosine kinase
inhibitor IV decreased the expression of p-PDGFR-b and p-PI3K.
Both PDGFR tyrosine kinase inhibitor IV and a PI3K inhibitor
(Wortmannin) decreased the expression of p-Akt, pCREB, and Bcl-2
while increasing the expression of Bax. Taken together, the findings
of the present study suggest a novel mechanism underlying uPAR
and cathepsin B-mediated regulation of Bcl-2 and Bax in gliomas.
Results
Downregulation of uPAR and cathepsin B induces
apoptosis by collapsing mitochondrial membrane
potential
To gain insight into the molecular roles of uPAR and cathepsin B,
we knocked down the expression of these molecules using siRNA in
U251 and 5310 glioma cells and then analyzed the effect on
apoptosis. Western blot analysis showed that uPAR and cathepsin B
expression was significantly decreased with pU, pC and pCU
(Figs. 1A–B). Quantification of protein bands revealed that uPAR
expression decreased by 88% in U251 cells and 68% in 5310 cells
with pU (p,0.01). Similarly, cathepsin B expression was reduced by
76% in both cell lines when treated with pC (p,0.01). Cells treated
with pU did not show appreciable difference in cathespin B
expression as compared to controls. Similarly, cells treated with pC
did not show any significant difference in expression of uPAR as
compared to controls (90%). pCU-treated cells showed 95%
decreased expression of uPAR in both U251 and 5310 cells.
Cathepsin Bexpression inpCU-treated cells was significantly reduced
by 90% (Fig. 1C). Immunoblot analysis for GAPDH expression
revealed equal loading. Analysis of apoptotic cell distribution by
FACS analysis showed that silencing of uPAR and cathepsin B
expression significantly increased the apoptotic cell population in
both U251 and 5310 cells (Fig. 1D). Cell cycle distribution in
histograms showed that the percentage of apoptotic cell population
was 2.8% in untreated U251 cells, 2.2% in SV-treated U251 cells,
70% in pU-treated U251 cells, 61% in pC-treated U251 cells, 79% in
pCU-treated U251 cells, 2.5% in untreated 5310 cells, 3.0% in SV-
treated 5310 cells, 72% in pU-treated 5310 cells, 65% in pC-treated
5310 cells, and 76% in pCU-treated 5310 cells (Fig. 1E).
In addition, TUNEL assay results for cells at 72 hrs post-
transfection indicated a significant increase in TUNEL-positive
cells in both U251 and 5310 cells (Fig. 1F). Quantification of
apoptotic cells revealed that in 5% untreated, 6% SV-treated, 30%
pU-treated, 25% pC-treated, and 58% pCU-treated U251 cells
were apoptotic. 5% untreated, 6% SV-treated, 48% pU-treated,
38% pC-treated, and 64% pCU-treated 5310 cells were apoptotic
as compared to DAPI stained cells (100%)(Fig. 1G). DNA
fragmentation in treated samples further confirmed apoptosis
(Supplementary Fig. S1). Analysis of mitochondrial membrane
potential collapse by fluorescence microscopy using MitoLight dye
indicated that pU, pC and pCU caused significant loss of
mitochondrial membrane potential (Dym) as indicated by a
decrease in red fluorescence as compared to controls (Fig. 1H).
Taken together, the data indicate that uPAR and cathepsin B play
pivotal roles as anti-apoptotic molecules in glioma, and targeting
uPAR and cathepsin B activity led to the induction of apoptosis.
RNAi-mediated downregulation of uPAR and cathepsin B
increases the expression of pro-apoptotic genes and
decreases the expression of anti-apoptotic genes
To evaluate the expression of apoptosis-related proteins, SV-
and pCU-transfected U251 and 5310 cell lysates were analyzed
using RayBio Human Apoptosis Antibody Array kit. A compar-
ison of pCU- and SV-transfected cells indicated that expression of
Bax, caspase-3 and p27 increased while expression of Bcl-2
decreased with pCU in U251 cells. In pCU-treated 5310 cells, the
expression of BAX increased while Bcl-2 decreased (Fig. 2A).
Quantification of protein signals by densitometry revealed that
both BAX and capsase-3 increased 2.5-fold and p27 increased 5.4-
fold. In contrast, Bcl-2 decreased 8.6-fold in pCU-treated U251
cells. In pCU-treated 5310 cells, Bax increased 3.6-fold; however,
Bcl-2 decreased 3.8-fold (Fig. 2B). To confirm these results, we
determined the expression of Bcl-2 and Bax by western blot
analysis using antibodies specific to Bcl-2 and Bax. The results
showed that the expression of Bcl-2 was significantly decreased
with pU, pC, and pCU in both U251 and 5310 cells. In contrast,
expression of Bax significantly increased with these treatments
(Fig. 2C). Densitometric analysis reveals that the Bcl-2/Bax ratio
decreased by 65% with pU, 60% with pC, 75% with pCU in
U251 as compared to controls. Similarly, in 5310 cells, the Bcl-2/
Bax ratio decreased by 85% with pU, 80% with pC, and 90% with
pCU as compared to controls (Fig. 2D). To determine whether
decreased Bcl-2 expression and increased Bax expression were
caused by gene transcription, we examined the transcript levels of
Bcl-2 and Bax using semi-quantitative RT-PCR. The results show
that expression of Bcl-2 mRNA was significantly decreased by pU,
pC, and pCU in both U251 and 5310 cells (Fig. 2E). Furthermore,
quantification by densitometry revealed that the Bcl-2/Bax ratio
(at the mRNA level) decreased by 80%, 85%, and 90% with pU-,
pC- and pCU-treatments. The results were similar in both U251
and 5310 cells compared to the controls (Fig. 2F).
Caspase dependent and independent apoptosis
To reveal the involvement of caspases, we used a broader caspase
inhibitor, Z-Asp-2, 6-dichlorobenzoyloxymethylketone, to examine
its ability to prevent apoptosis caused by uPAR and cathepsin B
gene silencing. Analysis of cell distribution by FACS showed that
pretreatment with the broad caspase inhibitor at 40 mM rescued the
apoptosis in pCU-transfected U251 cells, but failed to prevent
apoptosis in 5310 cells (Fig. 3A). Cell cycle distribution in histogram
showed that the percentage of apoptotic cell population (G0–G1)
was 4% in untreated, 5% in SV-treated, and 13% in pCU-treated
U251 cells; in contrast, the apoptotic population was 7% in pCU-
transfected cells pretreated with the broad caspase inhibitor. In
5310 cells, the percentage of the apoptotic cell population was 4%
and 6% in untreated and SV-transfected cells, respectively.
However, the percentage of the apoptotic cell population was
27% in both pCU-transfected cells and pCU-transfected cells
pretreated with the broad caspase inhibitor (Fig. 3B). The above
results indicate caspase-dependent apoptosis in U251 cells and
caspase-independent apoptosis in 5310 cells.
uPAR and Cathepsin B Silencing
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of cytochrome c from mitochondria into cytosol and
activation of caspase-3, caspase-9 and CAD in U251 cells
We performed a colorimetric assay for caspase activity in uPAR
and cathepsin B siRNA-induced apoptosis in U251 cells to explore
the roles of activated caspase-3 and caspase-9. We observed
substantial increases in the activity of caspase-3 and caspase-9 with
pU and pC and a significant increase with pCU when compared to
controls (Supplementary Fig. S2). These results were confirmed by
western blot analysis. Figure 3C showsthatpUandpCresulted inthe
substantial cleavage of caspase-3, caspase-9 and CAD as compared to
controls. Notably, pCU significantly increased cleaved caspase-3,
c a s p a s e - 9a n dC A D .T h ec l e a v a g eo fc a s p a s e si sa i d e db yt h er e l e a s e
of caspase-activating factors, particularly cytochrome c, from the
mitochondrial membrane into the cytosol [23]. Hence, we
determined cytochrome c levels in both mitochondrial and cytosolic
fractions using western blot analysis. In the present study, we found
significantly increased signal for cytochrome c in the cytosolic
fractions of pU-, pC- and pCU-treated U251 cells as compared to
Figure 1. RNAi-mediated depletion of cathepsin B and uPAR induces mitochondrial apoptosis in U251 and 5310 cells. (A–B) Western blot
analysis of uPAR and cathepsin B expression in U251 and 5310 cells 72 hrs after transfection with SV, pU, pC and pCU. (C) Quantitative analysis of uPAR and
cathepsin B expression by densitometry. Results from three independent experiments are shown as mean 6 SD (**p,0.001). GAPDH was used as a loading
control. (D) Cell cycle distribution of U251 and 5310 cells. Propidium iodide-stained cells were analyzed for DNA content using flow cytometry. (E) Histograms
represent the percentage of cells in G0/G1, S and G2/M phases. The data represent one of three independent experiments. Values are mean 6 SD of three
different experiments (**p,0.001). (F) Cells were stained for apoptosis using TdT-mediated dUTP nick end-labeling (TUNEL) assay. Data shown are from a
representative experiment. (G) Quantification of apoptotic cells expressed as percent of DAPI-stained cells. Bars represent the mean 6 SD of three
experiments (*p,0.05; **p,0.001). (H) Analysis of mitochondrial membrane potential using MitoLight kit. Cells were collected, incubated with MitoLight dye
for 20 min at room temperature, and observed for fluorescence; red fluorescence indicates healthy cells while green fluorescence indicates apoptotic cells.
doi:10.1371/journal.pone.0013731.g001
uPAR and Cathepsin B Silencing
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in mitochondrial fractions (Fig. 3D). Once released into the cytosol,
cytochrome c activates apoptotic protease-activating factor (Apaf-1),
which together with caspase-9, forms an active holoenzyme complex
known as apoptosome [23]. To test whether uPAR and cathepsin B
knockdown interferes with the formation of apoptosome complex, we
performed immunoprecipitation of caspase-9 with anti-caspase-9
antibody, followed by immunoblot analysis with anti-Apaf-1
antibody. The results indicate that Apaf-1 was significantly
immunoprecipitated with caspase-9 in pU-, pC- and pCU-treated
samples as compared to controls (Fig. 3E).
Downregulation of uPAR and cathepsin B activates the
nuclear translocation of apoptosis-inducing factor (AIF)
in 5310 glioma xenograft cells
To determine the nuclear localization of AIF, the expression
levels of AIF were determined by western blot analysis of the
cytoplasmic, mitochondrial and nuclear extracts of untreated and
treated 5310 cells. From the results, we observed that AIF levels
were remain same in the cytoplasmic extract of all treatments (data
not shown). AIF levels were decreased in mitochondrial fractions of
pU, pC and pCU treated 5310cells. However, nuclear localization
ofAIF wasincreased significantlywhenuPAR andcathepsinB were
downregulated either individually or simultaneously (Fig. 3F).
Downregulation of uPAR and cathepsin B through siRNA
treatment interferes with intracellular signaling events
To further elucidate uPAR and cathepsin B-mediated molecular
signaling in the regulation of Bcl-2 and Bax expression, we
investigated the involvement of the PI3K/Akt pathway by western
blot analysis. Total PI3K (data not shown) and Akt expression
levels remained more or less unchanged whereas the levels of p-
PI3K p85a (Y 508) and p-Akt (S473) were significantly decreased
with pCU transfection in both U251 and 5310 cells (Figs. 4A–B).
Figure 2. Effect of uPAR and cathepsin B downregulation on the expression of pro- and anti-apoptotic molecules. (A) Expression of
pro- and anti-apoptotic molecules in U251 and 5310 cells 72 hrs after transfection with SV or pCU. Human apoptosis antibody arrays were exposed to
cell lysates and processed as per the manufacturer’s instructions. (B) Densitometric analysis and graphical representation of fold change of pro- and
anti-apoptotic molecules. (C) Western blot analysis of Bcl-2 and Bax expression in U251 and 5310 cells 72 hrs transfection. The blots were stripped
and re-probed with GAPDH antibody to verify equal loading. The experiments were repeated three times and representative blots are shown. (D)
Densitometric analysis showing the Bcl-2/Bax ratio in U251 and 5310 cells. Columns: mean of triplicate experiments; bars: SE; **p,0.001. (E) Semi-
quantitative RT-PCR analysis of Bcl-2 and Bax mRNA expression in pU-, pC- and pCU-transfected U251 and 5310 cells. Total RNA was extracted 72 hrs
after transfection, and cDNA was synthesized as described in Materials and Methods. PCR was set up using first-strand cDNA as the template for Bcl-2,
Bax and GAPDH. (F) Densitometric analysis showing the Bcl-2/Bax mRNA ratio. Columns: mean of triplicate experiments; bars: SE; **p,0.001,
significant difference from untreated control or SV-transfected control.
doi:10.1371/journal.pone.0013731.g002
uPAR and Cathepsin B Silencing
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of PI3K and mediate uPA/uPAR signaling, so we next investi-
gated the hypothesis that PDGFR-b serves as the accessory
transmembrane adaptor molecule of uPAR [24]. Figures 4A–B
show that expression of total PDGFR-b remained unchanged in
both U251 and 5310, cells but p-PDGFR-b (Y751) significantly
decreased with pCU transfection. To confirm these results, we
used PI3K inhibitor (Wortmannin) at 20 and 40 mg/mL and
Figure 3. Downregulation of uPAR and cathepsin B induced caspase-dependent apoptosis in U251 cells and caspase-independent
apoptosis in 5310 cells. (A) FACS analysis of pCU-transfected U251 and 5310 cells pretreated with 40 mM broad caspase inhibitor (Z-Asp-2, 6-
dichlorobenzoylmethylketone). (B) Histograms represent the percentage of cells in G0/G1, S and G2/M phases. The data represent one of the three
independent experiments. Values are mean 6 SD of three different experiments (*p,0.05, **p,0.001). uPAR and cathepsin B downregulation
induced activation of caspase-9, caspase-3, ICAD, CAD in pU-, pC- and pCU-treated U251 cells. (C) Western blot analysis for active caspase-9, caspase-
3, ICAD and CAD in U251 cells. (D) Expression of cytochrome c in mitochondrial and cytosolic fractions was determined by western blot analysis.
Cytochrome oxidase IV was used as a marker for mitochondrial fractions (MF); GAPDH was used for cytosolic fractions (CF). (E) Immunoprecipitation
of Apaf-1 from U251 cell lysates. Total cell lysates were subjected to immunoprecipitation using anti-caspase-9 antibody and then immunoblotted for
Apaf-1. Total lysates from SV-, pU-, pC- and pCU-treated U251 cells were separated into mitochondrial and nuclear fractions as per standard protocols
and immunoblotted for AIF. (F) Expression levels of AIF in mitochondrial (MF) and nuclear fractions (NF) were determined by western blot analysis.
Cytochrome oxidase IV was used as a marker for mitochondrial fractions; laminin B was used for nuclear fractions. Total lysates from SV-, pU-, pC- and
pCU-treated 5310 cells were fractionated into mitochondrial and cytosolic fractions as per standard protocols and immunoblotted for cytochrome c.
Immunoblots are representative of three experiments.
doi:10.1371/journal.pone.0013731.g003
uPAR and Cathepsin B Silencing
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concentrations. At a concentration of 40 mg/mL, the specific
inhibitor of PI3K significantly inhibited basal expression of p-Akt,
p-CREB (S133) and Bcl-2 and induced the expression of Bax in
both U251 and 5310 cells (Figs. 4C&D). At a concentration of
10 nM, PDGFR tyrosine kinase inhibitor IV significantly inhibited
the expression of p-PDGFR-b, p-PI3K, p-Akt, p-CREB and Bcl-2
and increased the expression of Bax (Figs. 4E&F).
uPAR and cathepsin B downregulation retards nuclear
translocation and affects DNA binding activity of CREB
It has been shown that Bcl-2 expression might be regulated by
the transcription factor CREB [25], so we investigated expression
and phosphorylation of CREB in nuclear extracts of U251 and
5310 cells using western blotting. The results depicted in
Figures 5A–B show that expression of total CREB was not
altered; however expression of p-CREB was significantly
decreased in the nuclear fraction of pCU-transfected U251 and
5310 cells as compared to controls. To further investigate the
effect of uPAR and cathepsin B downregulation on CRE binding
activity of CREB, we used antibody induced supershift analysis in
EMSA. Nuclear extracts from SV- and pCU- treated cells showed
supershift with strong binding when subjected to antibody induced
supershift in EMSA. However, the intensity of the band showing
supershift in pCU-treated cells was significantly decreased
(Figs. 5C–D, lane 5). In contrast, with either no antibody or
normal IgG antibody the CREB DNA binding mobility was not
affected (Figs. 5C–D, lanes1, 3, 4 and 6). Taken together, these
Figure 4. Downregulation of uPAR and cathepsin B using siRNA interferes with intracellular signaling events. U251 and 5310 cells
were transfected with SV, pU, pC or pCU. Untreated cells served as the control. After 72 hrs, cells were collected, and total cell lysates were prepared
and western blotted as per standard protocol using normal and phosphorylated forms of PI3K, Akt and PDGFR-b. (A–B) Expression of normal and
phosphorylated forms of PI3K, Akt and PDGFR-b in U251 and 5310 cells. Columns: mean of triplicate experiments; bars: SE; *p,005 and **p,0.001,
significant difference from untreated control or SV-transfected control. Effect of PI3K inhibitor (Wortmannin) and PDGFR tyrosine kinase inhibitor
(PTKI) on expression of p-PDGFR-b, p-PI3K p85a, Bcl-2 and Bax. U251 and 5310 cells were treated with 20 and 40 mg/mL of PI3K inhibitor
(Wortmannin;WN) for 48 hrs, and the expression levels of p-Akt, p-CREB, Bcl-2 and Bax were determined by western blotting using appropriate
antibodies. (C–D) Western blot analysis of p-AKT, p-CREB, Bcl-2 and Bax expression levels after treatment with the PI3K inhibitor. Separately, U251 and
5310 cells were treated with 5 nM and 10 nM PDGFR tyrosine kinase inhibitor (PTKI) for 48 hrs. Expression levels of p-PDGFR-b, p-PI3K, p-Akt, p-CREB,
Bcl-2 and Bax were determined by western blotting using appropriate antibodies. (E–F) Western blot analysis of p-PDGFR-b, p-PI3K, p-Akt, p-CREB,
Bcl-2 and Bax expression levels in U251 and 5310 cells treated with PDGFR tyrosine kinase inhibitor.
doi:10.1371/journal.pone.0013731.g004
uPAR and Cathepsin B Silencing
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the DNA binding activity of CREB.
DNA-binding activity of CREB was also determined by
colorimetric assay using the TransAM ELISA kit. To test the
specificity of DNA binding, the assay was also performed in the
presence of excess oligonucleotide containing a wild-type or
mutated CREB consensus binding site. At 20X excess, the wild-
type oligonucleotide prevents CREB binding to the probe
Figure 5. uPAR and cathepsin B downregulation retards nuclear translocation and decreases DNA binding activity of CREB. U251
and 5301 cells were transfected with SV, pU, pC or pCU for 72 hrs. Cell lysates were separated into nuclear (NF) and cytoplasmic fractions (CF) and
immunoblotted for p-CREB. Total cell lysates were probed for CREB. (A–B) Western blot analysis of p-CREB in nuclear and cytoplasmic fractions of
U251 and 5310 cells. Nuclear extracts were prepared from SV- (control) and pCU-transfected U251 and 5310 cells and supershift analysis of CREB
binding activity was carried out using EMSA. For supershift analysis, nuclear extracts were incubated with supershift specific CREB antibody (2.0 mg)
or IgG (2.0 mg) prior to incubation with CREB binding buffer. (C–D) Supershift analysis of CREB DNA binding activity in U251 and 5310 cells. The
experiments were performed three times and representative blots are shown. Nuclear extracts were prepared from SV-, pU-, pC- and pCU-transfected
U251 and 5310 cells, and DNA binding activity of CREB was determined by colorimetric assay using the TransAM ELISA kit. To test specificity, DNA
binding activity was tested in the presence of an excess of oligonucleotide containing a wild-type or mutated CREB consensus binding site. (E–F)
Inhibition of DNA binding activity of CREB by nuclear extracts of pU-, pC- and pCU-treated U251 and 5310 cells. The bars represent the mean 6 SD of
three different experiments. *Statistically different compared to controls and pU-, pU- and pCU-treated groups (**p,0.001).
doi:10.1371/journal.pone.0013731.g005
uPAR and Cathepsin B Silencing
PLoS ONE | www.plosone.org 7 October 2010 | Volume 5 | Issue 10 | e13731immobilized on the plate. Conversely, the mutated oligonucleotide
has little effect on CREB binding. The results show that without
probe, optical density (OD) at 450 nm was 2.55 in nuclear extracts
of untreated U251 and 5310 cells (control). In contrast, the OD
was 1.25 in both pU- and pC-treated nuclear extracts of U251
cells and 1.3 and 1.5 in pU- and pC-treated nuclear extracts of
5310 cells. However, OD of all nuclear extracts with wild-type and
mutated consensus oligonucleotides was 3, which indicates specific
binding of CREB with CREB responsive elements (Figs. 5E–F).
To further confirm CREB-mediated regulation of Bcl-2 and Bax,
we treated both U251 and 5310 cells with CREB siRNA for
48 hrs and determined the expression of CREB, Bcl-2 and Bax
using western blotting. The results indicate that expression levels
of CREB and Bcl-2 were significantly decreased with CREB gene
silencing in both U251 and 5310 cells. However, expression of
BAX remains same in controls and siRNA treated U251 and 5310
cells (Supplementary Fig. S3).
pCU induces apoptosis, inhibits expression of uPAR,
cathepsin B and Bcl-2, and enhances expression of BAX in
vivo
To correlate the in vitro results with in vivo experiments, we
further investigated the effect of uPAR and cathepsin B down-
regualtion on apoptosis using U251 and 5310 cells in nude mice.
After the mice were implanted with U251 and 5310 cells as
explained in Materials and Methods, the mice were observed for
30 days. Tumor samples were then taken and paraffin-embeded
sections were prepared for immunohistopathological examination.
These in vivo experiments would be helpful to confirm our in vitro
data showing that uPAR and cathepsin B downregulation induces
apoptosis in the glioma cells. To check the apoptosis in in vivo,w e
have carried out TUNEL assay on paraffin-embedded brain tissue
sections. The results demonstrated significant DNA fragmentation
in pCU-treated brain tissue sections as compared to control
sections (Figs. 6A–B). Next, we determined expression of uPAR,
cathepsin B, Bcl-2 and Bax in brain tissue lysates and tissue
sections. Immunohistochemical analysis revealed that expression
levels of uPAR, cathepsin B and Bcl-2 were decreased in pCU-
treated brain tissue sections of both U251 and 5310 as compared
to controls. In contrast, expression of Bax was increased in pCU-
treated brain tissue sections as compared to controls (Figs. 6C–D).
Western blot analysis further confirmed that pCU significantly
inhibited the expression of uPAR, cathepsin B and Bcl-2 while the
expression of BAX increased in both U251 and 5310 brain tissue
lysates as compared to controls (Figs. 6E–F).
Discussion
uPAR and cathepsin B are overexpresssed in high-grade glioma,
and this overexpression strongly correlates with invasive cancer
phenotype and poor prognosis [26–29]. As stated earlier, RNAi
has emerged as potent technology for exploiting target genes in
glioma. As a preliminary assessment of the potential of RNAi
against uPAR and cathepsin B as a therapeutic agent in growth
inhibition, we assessed its in vitro apoptotic activity against U251
glioma and 5310 glioma xenograft cells. Transfection of glioma
cells with siRNA for uPAR and/or cathepsin B strongly inhibited
the expression of both proteins as previously reported [30]. When
glioma cells were transfected with the bicistronic construct pCU,
the morphology of cells became rounded and growth was inhibited
(data not shown), which is suggestive of apoptosis. Further, our
investigation using flow cytometric analysis and TUNEL assay
confirmed that cell death induced by pU, pC and pCU
transfection was due to induction of apoptosis.
Mitochondria are the central integrators and coordinators of
both intracelluar and extracellular signals that mediate caspase-
dependent and caspase-independent cell death [31]. Recently, it
has been reported that induction of mitochondrial apoptosis
requires the involvement of the Bcl-2 family, including apoptosis
inhibiting gene products (e.g., Bcl-2, Bcl-xL) and apoptosis
accelerating gene products (e.g., Bax, Bak, Bcl-xS, Bim) [32].
Loss of mitochondrial membrane potential is a prerequisite for
mitochondrial-mediated apoptosis as it is associated with the
reshuffling of Bcl-2 family members between the cytoplasm and
mitochondria. The Bcl-2 family is comprised of proteins, which
share a Bcl-2 homology (BH) region and undergo either
heterodimerization or homodimerizaton [33]. The ratio between
anti- and pro-apoptotic proteins is said to be a determinant for
tissue homeostasis because it influences the sensitivity of cells to
inducers of apoptosis [34,35]. Overexpression of Bcl-2 is reported
to cause inhibition of programmed cell death in many cell types,
and this anti-apoptotic function appears to be modulated by its
ability to heterodimerize with other members of the family,
especially the apoptosis-inducing Bax protein [36].
In this study, we have demonstrated that the downregulation of
uPAR and cathepsin B induced mitochondrial-mediated apoptosis
in the U251 glioma cell line and 5310 glioma xenograft cells and
was accompanied by the collapse of mitochondrial membrane
potential. We also noticed that downregulation of uPAR and
cathepsin B decreased the Bcl-2/Bax ratio. An earlier study
reported that downregulation of uPAR and cathepsin B initiated
partial extrinsic apoptotic cascade accompanied by the collapse of
mitochondrial membrane potential in SNB19 glioma cells [37].
Moreover, Kin et al. [38] reported that downregulation of uPAR
was associated with increased expression of the pro-apoptotic
protein Bax in glioma cells. Taken together, these results suggest
that uPAR and cathepsin B downregulation induced apoptosis by
modulating the Bcl-2/Bax ratio accompanied by collapse of
mitochondrial membrane potential.
In the present study, significant increases in caspase-3, Apaf-1
and cytochrome c were also observed with the downregulation of
uPAR and cathepsin B in U251 cells but not in 5310 cells (data not
shown). In contrast, in 5310 cells, the downregulation of uPAR
and cathepsin B was accompanied by the nuclear translocation of
AIF from the mitochondria. Cytochrome c combines with Apaf-1,
caspase-9 and ATP to form the apoptosome in the cytoplasm [39].
AIF is another mitochondrial protein that is translocated to the
cytosol and nucleus during apoptosis [40]. In the nucleus, AIF is
thought to increase chromatin condensation and large-scale DNA
fragmentation [41]. Interestingly, a broad caspase inhibitor, Z-
Asp-2-6-dichlorobenzoylmethylketone, prevented pCU-induced
apoptosis in U251 cells but fail to reduce the apoptotic percentage
of 5310 xenograft cells, which indicates caspase-dependent
apoptosis in U251 cells and caspase-independent apoptosis in
5310 cells. Similarly, Shih et al. [42] reported that cadmium
induced a caspase-independent apoptotic pathway involving
mitochondria-mediated translocation of AIF in normal human
lung cells. Further, Tae-Jin Lee et al. [43] also reported caspase-
dependent and caspase-independent apoptosis in human leukemic
U937 cells.
The translocation of AIF and release of cytochrome c would
occur after the collapse of mitochondrial membrane potential.
However, mechanisms of membrane permeabilization are still
matter of debate. Irrespective of the exact mechanisms, the anti-
apoptotic members of the Bcl-2 family tend to stabilize the barrier
function of mitochondrial membranes, whereas pro-apoptotic Bcl-
2 family proteins destabilize it [44]. uPAR is a GPI-anchored cell
surface protein known to be associated with pro-uPA and
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proteins, including platelet-derived growth factor receptor (PDGFR)
for its non-proteolytic functions [46]. Recently, a direct interaction of
uPAR with PDGFR beta in macrophages [24] and vascular smooth
muscle cells [44] by the immunefluorescence approach, immuno-
precipitation and chemical cross linking experiments have been
Figure 6. RNAi-mediated downregulation of uPAR and cathepsin B induces apoptosis in pre-established intracranial tumors.
Intracranial tumors were established in nude mice by injecting U251 and 5310 cells that were treated with SV and pCU as described in Materials and
Methods. (A–B) The brains were embedded in paraffin, sectioned and stained for apoptosis by TdT-mediated nick end-labeling (TUNEL) followed by
DAB staining. Nuclei were counterstained with methyl green. Data shown are representative of five fields. Brown stain around green nuclei indicates
apoptotic cells. (C–D) Immunohistochemical analysis of uPAR, cathepsin B, Bcl-2 and Bax was performed in paraffin-embedded U251 and 5310 tumor
sections. Appropriate protein-specific antibodies were used. Fields with brown staining as a result of DAB interaction were scored for protein
expression. (E–F) uPAR and cathepsin B, Bcl-2 and Bax expression was detected in tumor tissue lysates from intracranial tumors of mice that received
SV and pCU. Results are representative of three separate experiments.
doi:10.1371/journal.pone.0013731.g006
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signaling might be indirect and possibly through uPAR.
In the current study, western blot analysis using phospho-
specific antibodies confirmed that expression of p-PDGFR-b,p -
PI3K and p-Akt were significantly decreased with the downreg-
ulation of uPAR and cathepsin B in both U251 and 5310 cells.
However, this protein phosphorylation was inhibited by pre-
treatment with PDGFR tyrosine kinase inhibitor IV and PI3K
inhibitor. It is well known that tyrosine kinase activity of PDGFR-
b was found to be decisive for mediating downstream signaling.
Duronio [47] recently reported that PDGFR-b is associated with
PI3K/Akt-mediated cell survival. These results further confirm
that uPAR-initiated signaling is mediated though PDGFR-b and
the PI3K/Akt pathway.
Recently, CREB was reported to be activated as a transcription
factor by phosphorylation at Ser-133 through several signaling
pathways, including PI3K/Akt [48]. Pugazhenthi et al. [49]
reported that Akt/protein kinase B upregulates Bcl-2 expression
through cAMP-response element-binding protein. CREB plays a
key role in regulating neuronal survival and appears to be a
primary transcription activator of the anti-apoptotic gene, Bcl-2
[50,51]. CREB mediates regulation of gene expression via its
binding to a CRE in the promoter region [52].
In this study, western blot analysis of cytoplasmic and nuclear
fractions showed that uPAR and cathepsin B downregulation
retarded the translocation of p-CREB in both U251 and 5310
cells. In addition, analysis of DNA binding activity by EMSA and
ELISA revealed that uPAR and cathepsin B downregulation also
affected DNA binding activity of CREB. To our knowledge, this is
the first report on the uPAR and cathepsin B-mediated regulation
of DNA binding activity of CREB in glioma. Moreover,
knockdown of CREB using siRNA significantly decreased
expression of Bcl-2 but not Bax. Further, use of a PI3K inhibitor
significantly decreased the expression of both Bcl-2 and Bax.
These results suggest that uPAR and cathepsin B downregulation
suppressed Bcl-2 expression possibly though inhibition of the PI3/
Akt pathway and regulation of DNA binding activity (transcrip-
tional) of CREB. However, Bax levels might be enhanced by
retaining Bax in the cytoplasm. This is an accordance with an
earlier study that reported PI3K/AKT activity was essential for
retaining Bax in the cytoplasm [18].
It has been previously demonstrated that in vivo treatment of
pre-established intracranial tumors with plasmids expressing
siRNA for uPAR and cathepsin B significantly inhibited tumor
growth in glioma [53]. In this study, we observed significant cell
death in pCU-treated U251 and 5310 brain tissue sections. In
addition, immunohistochemical analysis for Bcl-2 and Bax in
tumor brain sections treated with pCU and western blot analysis of
Bcl-2 and Bax in brain tissue lysates strongly confirmed our in vitro
results. Further, simultaneous downregulation of two molecules
using bicistronic vectors proved to be more effective than
specifically targeting a single gene/molecule [54]. However, the
mechanism of cell cycle and apoptosis is highly complex and
involves coordinated regulation of several molecules. Each of these
molecules might have a specific and independent role in apoptosis;
hence the effect is not always synergistic [55]. Studies have also
shown that the cellular proteases can either act independently or
coordinate with other proteases in the process of invasion,
angiogenesis and apoptosis [56,57]. In conclusion, downregulation
of uPAR and/or cathepsin B induced mitochondrial-mediated
apoptosis by modulating the Bcl-2/Bax ratio via inhibition of
PDGFR-b and the PI3K/Akt pathway (Fig. 7). Taken together,
our results suggest uPAR and cathepsin B are promising potential
therapeutic targets for glioma.
Materials and Methods
Ethics Statement
The Institutional Animal Care and Use Committee of the
University of Illinois College of Medicine at Peoria, Peoria, IL,
USA approved all surgical interventions and post-operative animal
care. The consent was written and approved. The approved
protocol number is 851, dated November 20, 2009.
Cell culture and transfection conditions
We used the U251 glioblastoma cancer cell line (obtained from
ATCC) and 5310 glioblastoma xenograft cells (kindly provided by
Dr. David James, University of California, San Francisco) in this
study. U251 and 5310 cells were grown in DMEM/F12 medium
and RPMI 1640 medium, respectively and supplemented with
10% FBS and 1% penicillin/streptomycin. After overnight
culturing in serum-free medium, cells were transfected with
scrambled vector (SV), puPAR (pU), pCathepsin B (pC), or a
bicistronic construct comprised of puPAR and pCathepsin B
(pCU) for 72 hrs using FuGene according to manufacturer’s
instructions (Roche Applied Science, IN). For CREB knockdown,
U251 and 5310 cells were transfected with CREB siRNA for
48 hrs using FuGene according to manufacturer’s instructions
(Cell Signaling Tech., Danvers, MA).
Western blotting and immunoprecipitation
U251 and 5310 glioma cells or brain tissues were harvested as
previously described [58]. Equivalent amounts of total protein
(30–50 mg per lane) were loaded onto 6–14% acrylamide gels,
resolved by electrophoresis, and electrotransferred onto nitrocel-
lulose membranes. Membranes were blocked and subsequently
Figure 7. Schematic representation of proposed molecular
mechanisms involved in the regulation of mitochondrial-
mediated apoptosis via PDGFR b and the PI3K/Akt pathway
in uPAR and cathepsin B-depleted glioma cells.
doi:10.1371/journal.pone.0013731.g007
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of the antibodies used in this study from Santa Cruz Biotechnology
(Santa Cruz, CA) except for anti-PDGFR-b,a n t i - p - P D G F R - b,a n t i -
Akt, anti-p-Akt, anti-PI3K, anti-p-PI3K, anti-CREB, anti-p-CREB
(S133), anti-Bcl-2, and anti-Bax, which were supplied by Cell
Signaling (Boston, MA). Primary antibodies were detected with
horseradish peroxidase (HRP)-conjugated secondary antibody raised
against the corresponding species for 1 hr at room temperature.
Proteins on membranes were developed using Pierce ECL Western
Blotting Substrate according to manufacturer’s instructions (Thermo
Scientific Inc, Rockford, IL). Protein content was normalized against
the GAPDH level, which was used as a loading control.
Caspase-9 was immunoprecipitated from 300 mg of total protein
using anti-caspase-9 antibody and protein A coupled with G
agarose beads (20 mg). The precipitates were washed five times
with lysis buffer and once with PBS. The pellet was then
resuspended in 1X sample buffer [50 mM Tris, (pH 6.8),
100 mM bromophenol blue, and 10% glycerol], incubated at
90uC for 10 min before electrophoresis to release the proteins
from the beads, and then immunoblotted for Apaf-1.
Cell cycle analysis
Phases of cell cycle were analyzed using flow cytometry as
described previously [59]. Cells transfected with SV, pU, pC, pCU
or pCU + pretreatment with broad caspase inhibitor were
trypsinized, washed with 1X PBS, and incubated with 1 mL of
propidium iodide for 30 min in the dark. The DNA content of
these cells was measured based on the presence of propidium
iodide (PI)-stained cells (Sigma Aldrich, St. Louis, MO). Flow
cytometric analysis was carried out on at least 10,000 cells from
each sample, and cell cycle data were analyzed using a FACS
Calibur flow cytometer (BD BioSciences, San Jose, CA) with an
excitation wavelength of 488 nm and an emission wavelength of
530 nm.
TUNEL assay
TUNEL assay was performed with adherent cells [40] and
paraffin-embedded tissue sections [60] using In Situ Cell Death
Detection Kit (Roche Diagnostics Corp., Indianapolis, IL). After
transfection with SV, pU, PC, or pCU, cells were fixed with
buffered formaldehyde (pH 7.4) and incubated with a reaction
mixture containing biotin-dUTP and terminal deoxynucleotidyl
transferase for 1 hr. The slides were stained with DAPI, mounted
with cover slips, and positively fluorescein-labeled cells were
visualized with fluorescence microscopy, quantified, and expressed
as percent compared to DAPI stained cells. For tissue sections,
after deparaffinization and rehydration, tissue sections were
pretreated with sodium chloride-sodium citrate buffer (pH 7.0)
at 80uC for 20 min, followed by thorough washing in distilled
water. Subsequently, sections were digested with Proteinase K for
1 hr with gentle agitation at 37uC and digestion was stopped by
washing in running water. After protease treatment, tissue sections
were treated as described above and subsequently stained with
DAB via peroxidase-conjugated avidin and counterstained with
0.5% methyl green.
Visualization of mitochondrial permeability transition
Mitochondrial membrane potential changes were assayed with
MitoLight dye according to manufacturer’s instructions (Millipore,
Danvers, MA). After transfection with SV, pU, pC or pCU, cells
were incubated with pre-diluted MitoLight solution for 30 min.
Cells were washed twice with 1X incubation buffer, mounted with
cover slips, and observed immediately under a fluorescence
microscope.
Apoptosis array
Cell lysates from SV- and pCU-treated U251 and 5310 cells
were analyzed using a human apoptosis antibody array (RayBio-
tech, Norcross, GA) according to the manufacturer’s instructions.
Signal intensities were quantified by densitometry, and fold change
was calculated by comparing with controls.
Reverse transcription PCR (RT-PCR)
Total RNA was extracted from the transfected cells using
TRIZOL reagent (Invitrogen, Carlsbad, CA) as per standard
protocol. DNase-treated RNA was used as a template for reverse
transcription (Invitrogen) followed by PCR analysis using specific
primers for Bcl-2, Bax and GAPDH (Table 1). The PCR
conditions were as follows: 94uC for 5 min, followed by 35 cycles
of 94uC for 30 sec, 58uC for 45 sec, and 72uC for 45 sec. GAPDH
was used as an internal control.
DNA binding activity of CREB
The interaction of CREB protein with DNA present in the
nuclear extracts from SV- and pCU-treated U251 and 5310 cells
was determined by supershift analysis experiments in EMSA using
Pamomics kit according to manufacturer’s instructions Affymetrix
Inc, Fremont, CA). Briefly, nuclear extracts were incubated with
supershift specific antibody (2.0 mg) (Santa Cruz Biotechnology,
SC:271x) and normal IgG antibody (2.0 mg) for 30 min prior to
incubation with biotin-labeled CREB transcription probe. The
protein/DNA complexes were separated on a 6% non-denaturing
polyacrylamide gel, and then they were transferred to a nylon
membrane and detected using streptavidin-HRP and a chemilu-
minescent substrate.
DNA-binding activity of CREB was confirmed by ELISA (Active
Motif, which is based on multi-well plates coated with an
oligonucleotide containing the consensus binding site of the
transcription factor), according to the manufacturer’s recommen-
dations. Briefly, 10 mg of nuclear proteins were incubated for 2 hrs
in a 96-well plate pre-coated with a double-stranded oligonucleotide
containing the consensus CRE site (TGACGTCA). Specificity of
bindingwasalsodetermined usingwild-type and mutated consensus
oligonucleotides. Binding of p-CREB was determined with an anti-
Ser
133-pCREB rabbit antibody. Colorimetric reaction was then
performed with a HRP-conjugated, anti-rabbit IgG antibody, and
absorbance was measured at 450 nm in a spectrophotometer.
Subcellular fractionation
Fractionation of nuclear and cytosolic proteins was carried out
as previously described [40]. Fractionation of mitochondrial
proteins was done using a mitochondrial isolation kit (Sigma, St.
Louis, MO) according to manufacturer’s instructions. Briefly, cells
were suspended in cell lysis buffer and homogenized on ice using a
Dounce homogenizer (10–30 strokes) and centrifuged at 6006g for
Table 1. Genes analyzed by RT-PCR.
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fresh tube and centrifuged at 11,0006g for 10 min at 4uC. The
supernatant was discarded and the pellet was resuspended in
CellLytic M cell lysis reagent with a protease inhibitor cocktail
(1:100 [v/v]) and used to analyze mitochondrial proteins.
Immunohistochemical analysis of brain tumor sections
for Bcl-2 and Bax
Stereotactic implantation of untreated, SV-, or pCU-treated U251
and 5310 cells (1610
5) was performed using Alzet minipumps at the
rate of 0.25 mL/hr. Sacrifice of glioma-bearing mice and tumor
processing were done as previously described [61,62]. Five animals
were used per treatment condition. Immunohistochemical analysis
for Bcl-2 and Bax was performed using standard protocols.
Caspase activity assay
The activity of caspase-3 and caspase-9 was determined using
colorimetric assay according to manufacturer’s instructions
(Chemicon International Inc., Temecula, CA). The lysates were
transferred to a 96-well plate and treated with the respective
peptide substrate for each caspase conjugated with p-nitroaniline
(Ac-DEVD-pNA). After overnight incubation, OD was measured
at 405 nm using a microplate reader.
DNA laddering assay
DNA laddering assay was carried out as described previously
[63]. Briefly, untreated and treated cells were resuspended in PBS,
fixed in 70% ethanol, and incubated overnight at 220uC. Ethanol
was removed by centrifugation at 5000 rpm for 3 min, and the
pellet was resuspended in 0.2 M phosphate-citrate buffer (pH 7.8)
and kept at room temperature for 30 min. The pellet was then
spun down at 10,000 rpm for 5 min, mixed with 3 mL of NP-40
and 3 mL of RNase A, and then incubated at 37uC for 30 min.
After adding 3 mL of Proteinase K solution, the mixture was
incubated for an additional 30 min. An aliquot of each DNA
extract was then mixed with loading buffer and separated on a
1.5% agarose gel. DNA fragmentation was visualized under UV
light after staining with ethidium bromide.
Supporting Information
Figure S1 RNAi-mediated downregulation of uPAR and cathep-
sin B induces DNA fragmentation in U251 and 5320 cells.
Untreated and treated cells were fixed in 70% ethanol overnight
at 220uC. Ethanol was removed, and DNA was extracted and
separated on 1.5% agarose gels as described in Materials and
Methods. DNA fragmentation was visualized under UV light after
staining with ethidium bromide. Agarose gel electrophoresis pattern
of DNA obtained from U251 and 5310 cells after transfection with
SV, pU, pC or pCU. Arrow indicates 180 bp laddering.
Found at: doi:10.1371/journal.pone.0013731.s001 (0.60 MB TIF)
Figure S2 RNAi-mediated downregulation of uPAR and
cathepsin B enhances activity of caspase-3 and caspase-9 in
U251 and 5310 cells. Cell lysates were prepared from U251 cells
transfected with SV, pU, pC or pCU and treated overnight with
the respective peptide substrate for each caspase conjugated with
p-nitroaniline (Ac-DEVD-pNA). Activity of these proteases was
measured at 405 nm using a microplate reader. Bars represent the
mean 6 SD of three experiments (*p,0.05, **p,0.001).
Found at: doi:10.1371/journal.pone.0013731.s002 (0.03 MB TIF)
Figure S3 Effect of CREB knockdown on Bcl-2 and Bax
expression. U251(A) and 5310(B) cells were transfected with
CREB siRNA for 48 hrs, and the expression levels of total CREB,
p-CREB, Bcl-2 and Bax were determined by western blot analysis
using appropriate antibodies.
Found at: doi:10.1371/journal.pone.0013731.s003 (0.14 MB TIF)
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